Phyla Dermatology & Clinical Advisory Board
CLINICALLY TESTED
Reduction of Acne-Causing Bacteria in an 8-Week Study
90 PATIENTS | AGES 12–35 | 8 WEEKS | DOUBLE-BLIND PLACEBO CONTROLLED
90%
Up to 90% reduction in
C. acnes bacteria vs placebo
>70%
saw reduction of lesions as early as 4–8 weeks
100%
saw no topical side effects
93%
reported healthier-looking skin by 4 weeks
BEFORE
AFTER 8 WEEKS
Participant 01
Acne type: Blackheads, Hormonal
Age range: 20–30
Skin Type: Dry
BEFORE
AFTER 8 WEEKS
Participant 03
Acne type: Hormonal, Cystic
Age range: 20-30
Skin Type: Combination
Trusted by Dermatologists
A New Class of Treatment, Powered by Live Phages
Phyla uses naturally occurring bacteriophages that selectively target C. acnes. Unlike traditional treatments, phages eliminate acne-causing bacteria without disrupting the skin barrier or beneficial microbiome.
Targets C. acnes without affecting beneficial bacteria.
Phages evolve alongside bacteria, reducing resistance risk.
Maintains skin barrier health.
Targets C. acnes without affecting beneficial bacteria.
Phages evolve alongside bacteria, reducing resistance risk.
Maintains skin barrier health.
Proven in Clinics. Visible at Home.
Photos from everyday users. No filters, no post-processing.